Summary
The combination of alpha-interferon and 13-cis-retinoic acid has shown significant activity against a number of human tumors. We conducted a phase II trial to test whether the combination would have a major response rate of 30% or more in patients with refractory, metastatic melanoma. Eleven patients were treated on the study. Alpha-interferon was administered subcutaneously three times a week at a dose of 10 million U/m2 and 13-cis-retinoic acid was administered orally at a dose of 1 mg/kg/day. No patient achieved a partial or complete remission. The combination of alpha-interferon and 13-cis-retinoic acid is unlikely to have significantly higher therapeutic activity than alpha-interferon alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Legha SS: Current therapy for malignant melanoma. Semin Oncol 16 (Suppl):34–44, 1989
Meyskens FL, Jr., Gilmartin E, Alberts DS, Levine NS, Brooks S, Salmon SE, Surwit EA: Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66:1315–1319, 1982
Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents. Part I. Cancer Treat Rep 71:391–405, 1987
Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents. Part II. Cancer Treat Rep 71:493–515, 1987
Warrell RP, Frankel SR, Miller WH, Jr., Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic with tretinoin (All-trans-retinoic-acid). N Engl J Med 324:1385–1393, 1991
Lotan R, Hendrix MJC, Lippman SM: Retinoids in the management of melanoma in: Marks R (ed.) Retinoids and cell differentiation. Blackwell Sci Pub, Oxford, 1990, 133–149
Meyskens FL, Jr., Salmon SE: Inhibition of human melanoma colony formation by retinoids. Cancer Res 39:4055–4057, 1979
Edwards L, Jaffe P: The effect of topical tretinoin on dysplastic nevi. Arch Dermatol 126:494–499, 1990
Levine N, Meyskens FL, Jr.: Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet 2:224–226, 1980
Lippman SM, Shimm DS, Meyskens FL, Jr.: Nonsurgical treatments for skin cancer. J Dermatol Surg Oncol 14:862–869, 1988
Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK: 13-cis-Retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–241, 1992
Lippman SM, Kavanagh JJ, Parades-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH: 13-cis-retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245, 1992
Speigel RJ: The alpha interferons: clinical overview. Semin Oncol 14 (Suppl 2):1–12, 1987
Meyskens Jr., FL, Yamanishi DT, Buckmeier JA, Voboril JE: Expression of the retinoic acid receptors in human primary melanocytes and metastatic melanoma cell strains. Proc Am Assoc Cancer Res 33:745, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dhingra, K., Papadopoulos, N., Lippman, S. et al. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs 11, 39–43 (1993). https://doi.org/10.1007/BF00873908
Issue Date:
DOI: https://doi.org/10.1007/BF00873908